Skip to main content

Atrial Fibrillation clinical trials at UCLA

4 in progress, 3 open to eligible people

Showing trials for
  • Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

    open to eligible people ages 18 years and up

    Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.

    Los Angeles, California and other locations

  • Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation

    open to eligible people ages 22-85

    REACT-AF is a multicenter prospective, randomized, open-label, blinded endpoint (PROBE design), controlled trial comparing the current Standard Of Care (SOC) of continuous Direct Oral Anticoagulation (DOAC) use versus time-delimited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) in participants with a history of paroxysmal or persistent Atrial Fibrillation (AF) and low-to-moderate stroke risk.

    Los Angeles, California and other locations

  • Milvexian Versus Apixaban in Participants With Atrial Fibrillation

    open to eligible people ages 18 years and up

    The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-central nervous system (CNS) systemic embolism.

    Torrance, California and other locations

  • AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment

    Sorry, in progress, not accepting new patients

    The primary objective of this study is to evaluate the safety and effectiveness of the AtriCure CryoICE system in performing the Cox-Maze III lesion set, in conjunction with Left Atrial Appendage (LAA) exclusion using the AtriClip device.

    Los Angeles, California and other locations

Our lead scientists for Atrial Fibrillation research studies include .

Last updated: